More Sickened After Eating Diamond Shruumz Bars, Cones and Gummies
Medically reviewed by Drugs.com.
By Ernie Mundell HealthDay Reporter
WEDNESDAY, June 12, 2024 -- The number of people severely sickened after consuming mushroom edibles sold as Diamond Shruumz-brand Chocolate Bars, Cones or Gummies has risen, the U.S. Food and Drug Administration said Tuesday.
As of Monday, "a total of 12 illnesses have been reported from eight states," the FDA noted in an updated advisory. "All 12 people have reported seeking medical care; 10 have been hospitalized." No deaths have been reported.
Symptoms have included "seizures, central nervous system depression [loss of consciousness, confusion, sleepiness], agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting," the agency added.
The Diamond Shruumz-brand mushroom edible products are being marketed online and at smoke/vape shops, legal CBD/THC shops and other retail outlets nationwide. The FDA is asking retailers to stop selling the products.
The edibles pose a special danger to kids, the agency added.
"This product may appeal to children and teenagers as it is marketed as a candy," the FDA noted. "Parents and caregivers should consider discussing the information in this advisory with their children and take extra care to avoid this product being consumed by younger people."
Anyone who does become ill after consuming Diamond Shruumz-brand products should call the Poison Help Line at 800-222-1222 and let them know the product was consumed.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-06-12 21:15
Read more
- Current Tobacco Use Declining in U.S. Youth in 2024
- Skin Patch Uses 'Imperceptible' Electric Zaps to Heal Wounds Without Drugs
- Even at Low Levels, Arsenic in Drinking Water Could Raise Heart Risks
- Expanded Admission Screening Protocol for Candida Auris Beneficial
- IDSA: MVA-BN Vaccine Against Mpox Tolerated, Effective for Teens
- Childhood Attention Issues Show Links to Later Risk for Psychosis, Schizophrenia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions